Search the forums and you will find BPC-157 and TB-500 described as near-miraculous healing agents for tendons, ligaments, gut, and just about everything else. Search the published clinical literature and you find something very different: almost no controlled human trials at all. This is a report of what the peer-reviewed record contains, with attribution. It is not medical or dosing advice, and neither compound is approved for human use.
Two different molecules with two different evidence bases
BPC-157 ("body protection compound 157") is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. Most of the published work comes from a single research group led by Predrag Sikiric in Croatia, and almost all of it is in rats and mice.
TB-500 is a synthetic fragment marketed as "thymosin beta-4." That label is doing a lot of work. Thymosin beta-4 (Tβ4) is a 43-amino-acid actin-binding protein that has genuinely been studied in humans. TB-500, the product sold online, is a short synthetic fragment (roughly the actin-binding region), not the full protein used in those trials. So when a vendor cites "thymosin beta-4 clinical data," the trials they are gesturing at usually tested full-length Tβ4, not the fragment in the vial.
What the preclinical data show
In animal models, BPC-157 has reported effects on tendon, ligament, muscle, and bone healing, plus gut and vascular outcomes. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine by McGuire and colleagues at the University of Utah summarizes the proposed mechanisms (VEGFR2 signaling, nitric oxide pathways, ERK1/2) and describes the regenerative effects in animals as substantial. The same review is blunt about the other side of the ledger: human data are "extremely limited," amounting to roughly three small pilot studies (knee pain, interstitial cystitis, and a safety/pharmacokinetics study), and it concludes BPC-157 "should be considered investigational." (McGuire et al., Curr Rev Musculoskelet Med, 2025)
Preclinical promise is not the same as clinical proof. Effects seen in rodents at controlled doses routinely fail to reproduce in humans, and animal studies say nothing about long-term safety in people.
The human-trial gap
For BPC-157, there is no published, peer-reviewed, full-length randomized controlled trial demonstrating efficacy or safety for any indication. USADA notes a "concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions," and states plainly that because the compound "has not been extensively studied in humans, no one knows if there is a safe dose, or if there is any way to use this compound safely." (USADA) A Phase 2 placebo-controlled hamstring-strain trial (NCT07437547) is registered, but no results are published.
TB-500 has no controlled human efficacy trials of its own. The closest real human evidence sits with full-length Tβ4. The strongest example is an ophthalmic formulation, RGN-259 (0.1% Tβ4 eye drops), tested in a randomized, placebo-controlled, double-masked Phase 3 trial in neurotrophic keratopathy, published in International Journal of Molecular Sciences in 2022. The trial was small (10 on RGN-259, 8 on placebo) and closed early.
| Endpoint | RGN-259 | Placebo | p-value |
|---|---|---|---|
| Complete corneal healing at 4 weeks (primary) | 6/10 | 1/8 | 0.0656 (not significant) |
| Complete healing at day 43 | 5/10 | 0/8 | 0.0359 (significant) |
The primary endpoint missed conventional significance. The authors reported 16 adverse events across seven subjects, one judged treatment-related, and concluded the drops were safe in that small sample. (Sosne et al., Int J Mol Sci, 2022) That is a topical eye drop of the full protein, not an injected fragment for tendons. Reading it as support for TB-500 self-injection is a stretch the data do not back.
Safety: mostly unknown
The honest summary is that human safety is uncharacterized. The Department of Defense's Operation Supplement Safety states there is "little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans," that benefits have been shown only in animals, and that the FDA has cautioned against compounded BPC-157 over safety and contamination risks. Products are frequently sold as "research chemicals" labeled not for human consumption. (DoD OPSS) Because these are unapproved compounds made outside pharmaceutical quality systems, what is actually in a given vial (identity, purity, sterility, endotoxin) is not guaranteed without independent lab testing.
Regulatory and anti-doping status
- FDA: Neither BPC-157 nor TB-500 is approved for any human use. The FDA reviewed BPC-157 for pharmacy compounding and flagged it over concerns including immunogenicity, manufacturing impurities, and absent human safety data.
- WADA: BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 (non-approved substances), banned at all times, in and out of competition. S0 covers substances "not approved by any governmental regulatory health authority for human therapeutic use," such as drugs under preclinical or clinical development. (WADA S0) Athletes in tested sport face sanctions for use.
Bottom line
The gap between the marketing and the evidence is wide. BPC-157's case is built on animal studies from largely one group, with three small human pilots and no completed published RCT. TB-500's human story borrows credibility from full-length Tβ4 trials, mainly a small, mixed-result eye-drop study, that tested a different molecule by a different route. Both are unapproved, and BPC-157 is specifically WADA-prohibited. This article reports published evidence only; it is not medical advice, and these compounds are research-use-only and not approved for human consumption.